Idera Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 96
Rang # Quantité totale PI 13 648
Note d'activité PI 1,9/5.0    12
Rang # Activité PI 73 084
Symbole boursier IDRA (nasdaq)
ISIN US45168K4058
Capitalisation 101M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

35 4
14 2
39 1
1
 
Dernier brevet 2023 - Tlr9 modulators for treating cancer
Premier brevet 1993 - Antisense oligonucleotide inhibi...
Dernière marque 2019 - IDERA
Première marque 2003 - IMO

Industrie (Classification de Nice)

Derniers inventions, produits et services

2022 Invention Tlr9 modulators for treating cancer. The present disclosure relates to methods for treating cance...
2021 Invention Immune modulation with tlr9 agonists for cancer treatment. The present invention relates to meth...
Invention Use of a tlr9 agonist in methods for treating covid-19. The present invention is directed to use...
Invention Use of a tlr9 agonist in methods for treating covid-19. The present invention is directed to use ...
2020 Invention Immune modulation with tlr9 agonists for cancer treatment. The present invention relates to metho...
2019 Invention Treatment of cancer using tlr9 agonist with checkpoint inhibitors. The invention provides method...
Invention Tlr9 modulators for treating cancer. The present disclosure relates to methods for treating canc...
P/S Medical therapeutic preparations, namely, biologically active modulators, biologically active imm...
2017 Invention Compositions for inhibiting checkpoint gene expression and uses thereof. The present invention i...
Invention Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune res...
Invention Toll-like receptor 9 antagonist and methods of use thereof. The invention provides antagonist of...
Invention Compositions and methods for inhibiting target rna expression. The present invention relates to t...
Invention Potentiation of mmrna therapeutics. The present invention relates to the use of immune regulatory...
2016 Invention Compositions for inhibiting nlrp3 gene expression and uses thereof. The present invention is dir...
Invention Compositions for inhibiting nlrp3 gene expression and uses thereof. The present invention is dire...
Invention Compositions for inhibiting dux4 gene expression and uses thereof. The present invention is dire...
Invention Compositions for inhibiting dux4 gene expression and uses thereof. The present invention is direc...
Invention Compositions for inhibiting checkpoint gene expression and uses thereof. The present invention is...
Invention Toll-like receptor 9 antagonist and methods of use thereof. The invention provides antagonist of ...
P/S Medical therapeutic preparations, namely, nucleic acids as biologically active modulators, nuclei...
2015 Invention Treatment of cancer using tlr9 agonist with checkpoint inhibitors. The invention provides methods...
2014 Invention Compositions for inhibiting gene expression and uses thereof. The inventors have examined the me...
Invention Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8. The invention relates to th...
2011 Invention Stabilized immunomodulatory oligonucleotides. The invention provides immunostimulatory oligonucle...
Invention Compositions for inhibiting gene expression and uses thereof. The inventors have examined the mea...
2005 P/S Reagents for the detection of polymerase chain reactions for scientific or research use; diagnost...
P/S Reagents for the detection of polymerase chain reactions for scientific or research use; diagnos...
P/S Medical and scientific research in the area of oligonucleotides or chemical products; pharmaceuti...
2003 P/S immunomodulatory oligonucleotides, namely, ingredients that enhance or induce an immune response ...